Business
Respiri (ASX:RSH) share price on watch following FDA approval
The Respiri Ltd (ASX: RSH) share price is on watch today after the company advised it has received United States Food and Drug Administration (FDA) clearance for its Wheezo app.
About Respiri
Respiri is a software-as-a-service (SaaS) company supporting asthma patients to monitor and manage their asthma. The company views that asthma is often under-diagnosed and under-treated, creating a substantial burden to sufferers and their families.
Respiri has created an eHealth SaaS platform, ‘Wheezo’, that uses a device and app to measure, record and monitor asthma symptoms. The device records breath sounds over 30 seconds to be analysed in…
-
Noosa News22 hours agoBrisbane vs Collingwood live blog: Richmond selects Noah Balta as unbeaten Lions prepare for Magpies test
-
General21 hours agoNT Coalition candidate Lisa Siebert diverges from Jacinta Nampijinpa Price on royal commission call
-
General22 hours agoCanberra man named as doctor accused of rape after suppression order lifted
-
Noosa News24 hours agoPeter Dutton insists there’s enough water for his seven nuclear plants, contradicting shadow frontbencher